Skip to content
2000
Volume 4, Issue 3
  • ISSN: 1872-213X
  • E-ISSN: 2212-2710

Abstract

Omalizumab is a recombinant humanized monoclonal antibody. Use of omalizumab is reported to benefit significantly a subset of asthmatics patients with inadequately controlled moderate-to-severe persistent allergic asthma that is not controlled with high-dose inhaled corticosteroids. However, recent reports and patents suggest wider applications in asthma and related diseases. In this review unmet needs and future directions regarding the use of omalizumab in asthma are discussed. Better understanding of omalizumab's mechanisms of action on one hand and asthma and related pathogenesis on the other hand might contribute to the development of better future guidelines of omalizumab use in asthma patients.

Loading

Article metrics loading...

/content/journals/iad/10.2174/187221310793564209
2010-11-01
2025-09-15
Loading full text...

Full text loading...

/content/journals/iad/10.2174/187221310793564209
Loading

  • Article Type:
    Research Article
Keyword(s): asthma; Omalizumab; steroid resistant asthma
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test